S&P 500   5,081.00 (+0.22%)
DOW   38,911.00 (-0.10%)
QQQ   437.87 (+0.60%)
AAPL   181.61 (+0.10%)
MSFT   408.28 (+0.14%)
META   489.29 (+1.09%)
GOOGL   137.41 (+0.76%)
AMZN   174.83 (+0.96%)
TSLA   201.65 (-0.19%)
NVDA   793.53 (+2.18%)
NIO   5.68 (+4.60%)
AMD   186.05 (+5.39%)
BABA   74.46 (-0.17%)
T   17.03 (+0.41%)
F   12.42 (+0.98%)
MU   89.42 (-0.32%)
CGC   3.36 (+0.00%)
GE   155.90 (+0.19%)
DIS   111.63 (+0.75%)
AMC   4.38 (-12.22%)
PFE   26.98 (-0.22%)
PYPL   60.90 (+1.08%)
XOM   104.51 (+0.18%)
S&P 500   5,081.00 (+0.22%)
DOW   38,911.00 (-0.10%)
QQQ   437.87 (+0.60%)
AAPL   181.61 (+0.10%)
MSFT   408.28 (+0.14%)
META   489.29 (+1.09%)
GOOGL   137.41 (+0.76%)
AMZN   174.83 (+0.96%)
TSLA   201.65 (-0.19%)
NVDA   793.53 (+2.18%)
NIO   5.68 (+4.60%)
AMD   186.05 (+5.39%)
BABA   74.46 (-0.17%)
T   17.03 (+0.41%)
F   12.42 (+0.98%)
MU   89.42 (-0.32%)
CGC   3.36 (+0.00%)
GE   155.90 (+0.19%)
DIS   111.63 (+0.75%)
AMC   4.38 (-12.22%)
PFE   26.98 (-0.22%)
PYPL   60.90 (+1.08%)
XOM   104.51 (+0.18%)
S&P 500   5,081.00 (+0.22%)
DOW   38,911.00 (-0.10%)
QQQ   437.87 (+0.60%)
AAPL   181.61 (+0.10%)
MSFT   408.28 (+0.14%)
META   489.29 (+1.09%)
GOOGL   137.41 (+0.76%)
AMZN   174.83 (+0.96%)
TSLA   201.65 (-0.19%)
NVDA   793.53 (+2.18%)
NIO   5.68 (+4.60%)
AMD   186.05 (+5.39%)
BABA   74.46 (-0.17%)
T   17.03 (+0.41%)
F   12.42 (+0.98%)
MU   89.42 (-0.32%)
CGC   3.36 (+0.00%)
GE   155.90 (+0.19%)
DIS   111.63 (+0.75%)
AMC   4.38 (-12.22%)
PFE   26.98 (-0.22%)
PYPL   60.90 (+1.08%)
XOM   104.51 (+0.18%)
S&P 500   5,081.00 (+0.22%)
DOW   38,911.00 (-0.10%)
QQQ   437.87 (+0.60%)
AAPL   181.61 (+0.10%)
MSFT   408.28 (+0.14%)
META   489.29 (+1.09%)
GOOGL   137.41 (+0.76%)
AMZN   174.83 (+0.96%)
TSLA   201.65 (-0.19%)
NVDA   793.53 (+2.18%)
NIO   5.68 (+4.60%)
AMD   186.05 (+5.39%)
BABA   74.46 (-0.17%)
T   17.03 (+0.41%)
F   12.42 (+0.98%)
MU   89.42 (-0.32%)
CGC   3.36 (+0.00%)
GE   155.90 (+0.19%)
DIS   111.63 (+0.75%)
AMC   4.38 (-12.22%)
PFE   26.98 (-0.22%)
PYPL   60.90 (+1.08%)
XOM   104.51 (+0.18%)
NYSE:PLX

Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

$1.60
+0.06 (+3.90%)
(As of 10:32 AM ET)
Today's Range
$1.56
$1.61
50-Day Range
$1.42
$1.83
52-Week Range
$1.21
$3.55
Volume
68,498 shs
Average Volume
259,445 shs
Market Capitalization
$114.54 million
P/E Ratio
32.01
Dividend Yield
N/A
Price Target
$10.00

Protalix BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
536.9% Upside
$10.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Protalix BioTherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
40.00%
From $0.10 to $0.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

401st out of 958 stocks

Biological Products, Except Diagnostic Industry

65th out of 160 stocks


PLX stock logo

About Protalix BioTherapeutics Stock (NYSE:PLX)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PLX Stock Price History

PLX Stock News Headlines

PLX Mar 2024 1.500 call
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Will These 3 Biotech Stocks Make Gains in 2024?
PLX: More Regulatory Approvals
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Protalix: Q3 Earnings Snapshot
Protalix BioTherapeutics Inc. Q3 loss drops in line with estimates
PLX: Second Quarter Results
See More Headlines
Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Employees
193
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+525.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,930,000.00
Pretax Margin
18.52%

Debt

Sales & Book Value

Annual Sales
$63.63 million
Book Value
($0.21) per share

Miscellaneous

Free Float
68,023,000
Market Cap
$114.53 million
Optionable
Optionable
Beta
0.88
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














PLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protalix BioTherapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PLX shares.
View PLX analyst ratings
or view top-rated stocks.

What is Protalix BioTherapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12-month target prices for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 536.9% from the stock's current price.
View analysts price targets for PLX
or view top-rated stocks among Wall Street analysts.

How have PLX shares performed in 2024?

Protalix BioTherapeutics' stock was trading at $1.78 at the beginning of 2024. Since then, PLX stock has decreased by 11.8% and is now trading at $1.57.
View the best growth stocks for 2024 here
.

When is Protalix BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PLX earnings forecast
.

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSE:PLX) issued its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $10.35 million for the quarter, compared to analyst estimates of $7.64 million. Protalix BioTherapeutics had a trailing twelve-month return on equity of 62.80% and a net margin of 16.68%. During the same period in the prior year, the business earned ($0.11) EPS.

When did Protalix BioTherapeutics' stock split?

Protalix BioTherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Protalix BioTherapeutics' major shareholders?

Protalix BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.76%), Northern Trust Corp (0.69%), Vanguard Group Inc. (0.42%), Nuveen Asset Management LLC (0.38%), Bridgeway Capital Management LLC (0.29%) and Barclays PLC (0.18%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel.
View institutional ownership trends
.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PLX) was last updated on 2/29/2024 by MarketBeat.com Staff